Waters (BOVESPA:WATC34) - Stock Price, News & Analysis

WATC34 Stock Overview

Provides analytical workflow solutions in Asia, the Americas, and Europe. More details

WATC34 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	2/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Waters Corporation Competitors

West Pharmaceutical Services

NYSE:WST

US$22.0b

Mettler-Toledo International

NYSE:MTD

US$24.5b

Divi's Laboratories

NSEI:DIVISLAB

₹1.6t

Sartorius Stedim Biotech

ENXTPA:DIM

€16.4b

Price History & Performance

Summary of all time highs, changes and price drops for Waters
Historical stock prices
Current Share Price	US$511.50
52 Week High	US$511.50
52 Week Low	US$381.80
Beta	0.97
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	122.84%
Change since IPO	139.33%

Recent updates

Shareholder Returns

	WATC34	BR Life Sciences	BR Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how WATC34 performed against the BR Life Sciences industry.

Return vs Market: Insufficient data to determine how WATC34 performed against the BR Market.

Price Volatility

Is WATC34's price volatile compared to industry and market?
WATC34 volatility
WATC34 Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in BR Market	0%
10% least volatile stocks in BR Market	0%

Stable Share Price: WATC34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine WATC34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1958	7,900	Udit Batra	www.waters.com

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Waters Corporation Fundamentals Summary

How do Waters's earnings and revenue compare to its market cap?
WATC34 fundamental statistics
Market cap	R$122.66b
Earnings (TTM)	R$3.60b
Revenue (TTM)	R$16.77b

34.1x

P/E Ratio

7.3x

P/S Ratio

Is WATC34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
WATC34 income statement (TTM)
Revenue	US$2.91b
Cost of Revenue	US$1.17b
Gross Profit	US$1.74b
Other Expenses	US$1.11b
Earnings	US$622.64m

Last Reported Earnings

Sep 28, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	10.49
Gross Margin	59.73%
Net Profit Margin	21.43%
Debt/Equity Ratio	115.6%

How did WATC34 perform over the long term?

See historical performance and comparison

WATC34 Stock Overview

Risk Analysis

Waters Corporation Competitors

NYSE:WST

US$22.0b

NYSE:MTD

US$24.5b

NSEI:DIVISLAB

₹1.6t

ENXTPA:DIM

€16.4b

Price History & Performance

Recent News & Updates

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation Introduces TA Instruments Discovery Core Rheometer

Waters Corporation to Report Q2, 2024 Results on Jul 31, 2024

Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Recent updates

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation Introduces TA Instruments Discovery Core Rheometer

Waters Corporation to Report Q2, 2024 Results on Jul 31, 2024

Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns

Waters Corporation, Annual General Meeting, May 23, 2024

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Waters Corporation Launched OligoWorks SPE Workflow and Kits

Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation Boosts Resolution and Triples Scan Speed of Select Series MRT for Metabolomics and MS Imaging

Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023

Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023

Waters Corporation Announces Waters_Connect™ System Monitoring

Waters Corporation Announces Executive Changes

Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to Waters_Connect Informatics Platform

Waters Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Waters Automates Solid Phase Extraction of Biological, Food and Environmental Samples with Andrew+ Pipetting Robot

Waters Extends Capabilities of Flagship Ta Instruments Rheometer for Efficient and Repeatable Powder Analysis

Waters Corporation Provides Earnings Guidance for the Third Quarter Ending October 1, 2022 and Full Year Ending December 31, 2022

Waters Corporation to Report Q2, 2022 Results on Aug 02, 2022

Waters Corporation(NYSE:WAT) dropped from Russell 1000 Value-Defensive Index

Waters Corporation Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Waters Corporation Provides Earnings Guidance for the Quarter Ending July 2, 2022 and Full Year Ending December 31, 2022

Waters Corporation, Annual General Meeting, May 24, 2022

Waters Corporation Announces Resignation of John Ballbach from the Board of Directors

Waters Introduces Xevo TQ Absolute

Waters Corporation Provides Earnings Guidance for the First Quarter Ending April 2, 2022 and Year Ending December 31, 2022

Waters Corporation Introduces the Waters™ BioAccord™ System

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2021

Waters Corporation Introduces TRIOS AutoPilot Software

Waters Corp. Introduces the Waters Arc Premier System

Waters Corporation Introduces the Sars-Cov-2 Lc-Ms Kit (Ruo) to Advance Clinical Research of Infectious Diseases

Waters Corporation Provides Earnings Guidance for the Three Months Ended July 3, 2021 and for the Full Year Ended December 31, 2021

Waters Corporation Introduces A New Peptide Multi-Attribute Method Workflow for the Waters BioAccord LC-MS System

Waters Corporation Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector

Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link

Waters Corporation Introduces the OttoTM SPEcialist Positive Pressure Manifold

Waters Corporation's APGC-MS/MS System Accepted for Advanced Dioxin and Furan Analysis Following USEPA Approval of SGS AXYS Method 16130

Waters Corporation Appoints Pearl S. Huang to Board of Directors

Waters Corporation Announces CFO Changes

Megadalton Solutions, Inc. Announces Expansion of Collaboration with Waters Corporation

Waters Corporation Gives More Laboratories Access to Mass Spectrometry with Rapid, Easy, and Compact RADIAN ASAP System

Waters Corporation Introduces Acquity Premier Columns

Waters Corporation (NYSE: WAT) signed an agreement to acquire rheology instruments and services business of Rheometric Scientific, Inc. for $23 million.

Shareholder Returns

Price Volatility

About the Company

Waters Corporation Fundamentals Summary

34.1x

7.3x

Earnings & Revenue